← Oncology Approval Tracker

FDA DECISION ·

Jemperli

dostarlimab-gxly · GlaxoSmithKline

Accelerated approvalNew therapyEndometrial cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Feb 9, 2023

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with dMMR recurrent or advanced endometrial cancer by an FDA-approved test, after progression during or following a platinum-containing regimen.

LAMPGEN ANALYSIS

Why it matters

The initial accelerated approval targeted a mismatch repair-deficient population after platinum. FDA later granted traditional approval on February 9, 2023.

What research teams should watch

Retain MMR testing details and dates of platinum exposure and progression.

PRIMARY RECORDS

Sources